Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma
Open Access
Abstract
There are no reliable biomarkers for early diagnosis or prognosis evaluation in pancreatic ductal adenocarcinoma (PDAC). Multiple scRNA-seq datasets for PDAC were retrieved from online databases and combined with scRNA-seq results from our previous study. The malignant ductal cells were identified through calculating copy number variation (CNV) scores. The robust markers of malignant ductal cells in PDAC were found. Five immune-related signatures, including SPP1, LINC00683, SNHG10, LINC00237, and CASC19, were used to develop a risk score formula to predict the overall survival of PDAC patients. We also constructed an easy-to-use nomogram, combining risk score, N stage, and margin status. The expression level of SPP1 was related to the prognosis and immune regulators. We found that SPP1 was mainly expressed in ductal cells and macrophages in PDAC. In conclusion, we constructed a promising prognostic model based on immune-related signatures for PDAC using scRNA-seq and TCGA_PAAD datasets.Keywords
Funding Information
- the Natural Science Foundation of China (82171722, 81871954, 7212111)
- Beijing Municipal Natural Science Foundation (82171722, 81871954, 7212111)
This publication has 52 references indexed in Scilit:
- A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2Cancer Research, 2016
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature Genetics, 2015
- Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal AdenocarcinomaPLOS ONE, 2015
- Pancreatic cancer: from state-of-the-art treatments to promising novel therapiesNature Reviews Clinical Oncology, 2015
- Pancreatic AdenocarcinomaNew England Journal of Medicine, 2014
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaScience, 2014
- T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer ImmunotherapyCancer Discovery, 2014
- Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic AdenocarcinomaPLOS ONE, 2013
- Pancreatic cancerThe Lancet, 2011
- Analysis of the α4β1 Integrin–Osteopontin InteractionExperimental Cell Research, 2000